Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK Study of BMS-986504 in Advanced Solid Tumors
NCT06672523Phase 1Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of MRTX1719 in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed concentration at 2 weeks, Time of maximum observed drug concentration at 2 weeks and 17 more. Started Mar 2025; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06672523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672523.